Skip to main content

BIOFIRE® Respiratory 2.1 (RP2.1) Panel

The FDA De Novo authorized BIOFIRE RP2.1 Panel is a frontline test to help clinicians quickly diagnose respiratory infections, including COVID-19, influenza, RSV, and many others.

Product Overview

1 Test. 22 Targets. ~45 Minutes.

The BIOFIRE RP2.1 Panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. Fast and comprehensive, the BIOFIRE RP2.1 Panel offers a run time of about 45 minutes, enabling high efficiency and throughput on the BIOFIRE® FILMARRAY® 2.0 and the BIOFIRE® FILMARRAY® TORCH Systems. Rapid respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.

See "Technical Details" tab for full product menu.


COVID-19 and the Value of the Syndromic Approach

Study results suggest higher rates of co-infection between SARS-CoV-2 and other respiratory pathogens than previously reported. In some cases, as many as 20% of COVID-19 patients have co-infections with another respiratory virus.1 Because respiratory symptoms are similar and overlapping, a syndromic panel can provide fast, comprehensive answers and take the guesswork out of choosing which pathogens to test for.


Improve Clinical Outcomes

The first-generation BIOFIRE® FILMARRAY® Respiratory Panel has been shown to reduce length of stay and duration of antibiotic use.2 Optimize patient management with clinically actionable results.

Don’t Guess. Know.

The typical symptoms of a respiratory infection can be caused by many viruses and bacteria. Remove the guesswork with syndromic testing from bioMérieux. The BIOFIRE® FILMARRAY® Panels combine several possible pathogens into one rapid test, with results in about an hour. bioMérieux’s multiplex PCR technology is more sensitive than culture and can help inform timely optimal therapy.


Technical Details

  • Overall 97.1% sensitivity and 99.3% specificity (prospective specimens)3
  • SARS-CoV-2 98.4% PPA and 98.9% NPA4
  • Sample Type: Nasopharyngeal swab in transport media or saline

Panel Menu:


  • Adenovirus
  • Coronavirus 229E
  • Coronavirus HKU1
  • Coronavirus NL63
  • Coronavirus OC43
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Human metapneumovirus
  • Human rhinovirus/enterovirus
  • Influenza A virus
  • Influenza A virus A/H1
  • Influenza A virus A/H3
  • Influenza A virus A/H1-2009
  • Influenza B virus
  • Parainfluenza virus 1
  • Parainfluenza virus 2
  • Parainfluenza virus 3
  • Parainfluenza virus 4
  • Respiratory syncytial virus



  • Bordetella parapertussis
  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Mycoplasma pneumoniae

Service & Support

With the urgent nature of patient and community care, we take pride in addressing all concerns quickly and accurately. bioMérieux is dedicated to providing world class customer support 24 hours a day, 7 days a week, 365 days a year.

For assistance please contact our customer technical support team at:

To order, contact your regional sales representative or use the following contact information:


Technical & Supporting Documents


Get actionable answers faster with the BIOFIRE® Respiratory Panels.

Product availability varies by country. Consult your bioMérieux representative.



  1. Kim D, et al. (2020) JAMA. 323(20):2085-2086.
  2. Rogers B, et al. Arch. Path. & Lab. Med. 2015;139(5): 636-41.
  3. Based on the prospective portion of the clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel
  4. Overall performance based on prospective SARS-COV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, Data on file, BioFire Diagnostics.